New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For VAL;AVP;KORS;BYD;ZIOP;FOSL;QCOM;LVLT;BCS;NTWK;FB From The Last 14 Days
Check below for free stories on VAL;AVP;KORS;BYD;ZIOP;FOSL;QCOM;LVLT;BCS;NTWK;FB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
July 22, 2014
08:12 EDTLVLTLevel 3 announces planned executive management team
Subscribe for More Information
07:31 EDTBCSSenate Homeland Security & Government Affairs Committee to hold a hearing
Subscribe for More Information
07:16 EDTBCSBarclays plunges from 2nd to 12th in U.S. dark pool ranks after suit, FT says
Subscribe for More Information
07:15 EDTZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CAR]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
05:39 EDTVALValspar upgraded to Conviction Buy from Neutral at Goldman
Goldman Sachs upgraded Valspar to Conviction Buy from Neutral citing the valuation discount peers, the recovery in the U.S. housing market and momentum in the company's Australian business. The firm raised its price target for shares to $97 from $83.
05:27 EDTVALValspar upgraded to Conviction Buy from Neutral at Goldman
July 21, 2014
16:18 EDTLVLTNetflix says policy goal is for DOJ/FCC to block Comcast, TWC deal
Subscribe for More Information
16:00 EDTFBOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
14:19 EDTFBFacebook allowing users to save items
Subscribe for More Information
13:15 EDTFBGoogle ranked as top online video content property in June
Subscribe for More Information
09:38 EDTFBActive equity options trading on open
Subscribe for More Information
09:05 EDTKORSKors calls speculation of analyst 'heads up' false, unfounded, TheStreet says
Subscribe for More Information
09:00 EDTKORSMichael Kors weakness overdone, says Morgan Stanley
Subscribe for More Information
08:55 EDTFBFacebook July weekly volatility increases into Q2
Subscribe for More Information
08:11 EDTBCSWarnings sounded over Barclays dark pool months before NY AG, WSJ says
Subscribe for More Information
08:04 EDTKORSMichael Kors weakness a buying opportunity, says Topeka
Topeka said recent checks do not indicate substantial markdown or clearance activity in the Michael Kors brand, contrary to some reports. The firm would use recent weakness as a buying opportunity and reiterates its Buy rating and $117 price target.
07:15 EDTFBO'Reilly to hold a conference
Subscribe for More Information
07:08 EDTFBFacebook Q2 results likely to beat expectations, says Cantor
Subscribe for More Information
07:08 EDTFBFacebook struggles to find director of business operations at Instagram, BI says
Facebook has been struggling to find a new Director of Business Operations for Instagram ever since Emily White left for Snapchat seven months ago, Business Insider reports. Reference Link
06:57 EDTFBFacebook likely to report modest Q2 upside, says BofA/Merrill
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use